This study aims to understand why some people who have had COVID-19 develop scarring of the lungs and why some people recover more quickly than others.
A large number of people diagnosed with COVID-19 suffer from long term symptoms,
predominantly breathlessness and fatigue whether or not they were admitted to hospital. While
there are a number of causes of long-term breathlessness following COVID-19 one of the most
common, and potentially concerning with regards to long term prognosis is Interstitial Lung
Disease.
The fibrogenic potential of SARS-CoV-2 is currently unknown but is predicted to be
substantial based on the experience of previous coronavirus outbreaks and emerging data from
this pandemic.
The investigators do not yet understand how scarring occurs following SARS-CoV-2, nor why
there is resolution in some individuals and persistent or progressive disease in others. The
investigators therefore plan to undertake bronchoscopy (camera test into the lungs) to
examine for changes in the way the cells lining the lung behave, using genetics, and
differences in the bacteria living in the airways in patients whom have developed scarring
following COVID-19.
Inclusion Criteria:
- Evidence of SARS-CoV-2 PCR/Seropositive
- Presence of interstitial lung disease on CT
- Participant is willing and able to give informed consent for participation in the
study
- Aged 18 years or above
Exclusion Criteria:
- Confirmed ILD diagnosis prior to March 2020
- Patients with co-morbid disease that in the opinion of the investigators gives them an
expected life expectancy of less than one year will be excluded from the study.
- Use of steroids at baseline visit
University College London NHS Foundation Trust
London, United Kingdom
Royal Brompton Hospital
London, United Kingdom
Imperial College Healthcare Trust
London, United Kingdom
Manchester University NHS Trust
Manchester, United Kingdom